RenovoRx TAMP trial begins for borderline resectable pancreatic cancer
A biotechnology company announced that a first patient has enrolled in an investigator-initiated trial (IIT) testing a targeted drug-delivery approach (TAMP) for borderline resectable pancreatic cancer. The trial uses gemcitabine delivered via RenovoCath, a device that administers treatment through blood vessels near the tumor, with a plan to assess surgical margins and potential tumor response before surgery.
What is happening now
RenovoRx reports the first patient enrollment in the PRISM-TAMP IIT, which investigates using the company’s Trans-Arterial Micro-Perfusion (TAMP) delivery system to give the standard chemotherapy drug gemcitabine directly to the tumor area before surgery. The goal is to improve tumor response and possibly shrink the tumor before an operation, while also testing how safely this delivery method works in this setting.
Key facts you should know
- Topic: A trial combining RenovoRx’s delivery device with gemcitabine for pancreatic cancer that is close to being fully removable by surgery but not clearly resectable yet.
- Trial type: Investigator-initiated, meaning led by a university (University of Vermont) rather than the company.
- Purpose: To evaluate whether delivering chemotherapy directly to the tumor area improves surgical outcomes and tumor response.
- Stage: Early in patient enrollment; one patient enrolled, a second patient progressing toward treatment shortly after the start.
- Relevance: If successful, this approach could influence how some borderline cases are prepared for surgery.
Who could be affected and how
Direct beneficiaries would be patients diagnosed with borderline resectable pancreatic cancer who are candidates for neoadjuvant (pre-surgery) therapy. Doctors and medical centers participating in IITs may adopt learnings if results show safety and promise. The broader patient community should not assume immediate changes to standard care until trial results are published and reviewed.
Practical next steps for readers
- Monitor research updates: Look for results from this IIT and related trials to understand safety signals and any improvements in tumor response.
- Discuss options with a doctor: If you or a family member has borderline resectable pancreatic cancer, talk about current standard treatments and whether clinical trials could be appropriate.
- Understand terminology: Neoadjuvant means treatment given before surgery to improve outcomes; resectable refers to how completely doctors can remove a tumor with surgery; TAMP describes a drug-delivery method through arteries near the tumor.
Which sources did Setup in Bahrain review?
Setup in Bahrain reviewed the following source material before preparing this explanatory article.
The links remain visible so readers can inspect the evidence, compare dates and context, and confirm current requirements with the relevant authority.
- investingnews.com — evidence source reviewed for this article.
Information and responsibility notice: This article is general information based on the cited material available when published. It is not legal, tax, immigration, medical, financial, banking, or investment advice; it does not create a professional-client relationship; and it is not a guarantee of outcome, availability, accuracy, or eligibility. Rules, schedules, prices, and third-party information can change. Confirm material decisions with the relevant authority and an appropriately qualified adviser before acting.